This Registry is designed to provide long term clinical and virologic follow up in participants who have achieved sustained virologic response (SVR) while participating in a previous Gilead sponsored hepatitis C virus (HCV) study. This long term follow up study is observational and no treatment is provided for HCV.

Key Inclusion Criteria:

• Have previously participated in a Gilead-sponsored hepatitis C study and received at least one Gilead oral antiviral agent (OAV)
• Have achieved SVR in a Gilead-sponsored study, as defined in the original treatment protocol
• Provide written, informed consent
• Be willing and able to comply with the visit schedule and protocol-mandated procedures

Key Exclusion Criteria:

• Individuals planning to start a new course of hepatitis C therapy including any investigational drug or device during the course of the follow-up Registry
• History of clinically significant illness or any other major medical disorder that may interfere with follow up, assessments, or compliance with the protocol

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Participants who have achieved sustained virologic response (SVR) while participating in a previous Gilead sponsored HCV study.